Alto Neuroscience
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Alto Neuroscience generated cash of -$33,448,000, which is less than the previous year. Cash used in financing activities reached the amount of $68,130,000 last year. Net change in cash is therefore $34,204,000.
Cash Flow
| 2022 | -20.39M | -732K | 43.78M |
|---|---|---|---|
| 2023 | -33.44M | -470K | 68.13M |
ANRO Cash Flow Statement (2022 – 2023)
| 2023 | 2022 | |
|---|---|---|
Cash at beginning of period | 48.34M | 25.70M |
Operating activities | ||
Net income | -36.30M | -27.71M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||
Depreciation and amortization | 373K | 342K |
Stock-based compensation expense | 2.89M | 1.76M |
| Deferred income tax benefit | 2.89M | 1.76M |
| Changes in operating assets and liabilities: | ||
Accounts receivable, net | 325K | 1.15M |
Inventories | 0 | 0 |
Accounts payable | -632K | 1.00M |
Cash generated by operating activities | -33.44M | -20.39M |
Investing activities | ||
Purchases Of Investments | 0 | 0 |
Investments In Property Plant And Equipment | -470K | -732K |
Acquisitions Net | 0 | 0 |
Cash generated by investing activities | -470K | -732K |
Financing activities | ||
Common Stock Issued | 181K | 43K |
Payments for dividends | 0 | 0 |
Repurchases of common stock | 0 | 0 |
Repayments of term debt | 0 | 9.82M |
Cash used in financing activities | 68.13M | 43.78M |
Net Change In Cash | 34.20M | 22.63M |
Cash at end of period | 82.54M | 48.34M |
| Data source |